Core Viewpoint - Aohua Endoscopy (688212.SH) announced a plan for major shareholders to reduce their holdings by up to 1,252,840 shares, representing 0.93% of the total share capital, through centralized bidding and block trading methods [1][2]. Shareholding Structure - As of the announcement date, Gu Kang, Gu Xiaozhou, and their controlled entity, Shanghai Xiaozhou Optoelectronics Co., Ltd. (Xiaozhou Optoelectronics), collectively hold 41,822,800 shares, accounting for 31.06% of the total share capital [2][3]. - Xiaozhou Optoelectronics holds 3,132,100 shares (2.33%), Gu Kang holds 16,950,200 shares (12.59%), and Gu Xiaozhou holds 21,740,500 shares (16.14%) [2]. Reasons for Share Reduction - The share reduction is attributed to the funding needs of Su Min Investment Junxin (Shanghai) Industry Upgrade and Technology Innovation Equity Investment Partnership (Limited Partnership), a shareholder of Xiaozhou Optoelectronics [3]. Financial Performance - In 2024, Aohua Endoscopy achieved a revenue of 750 million yuan, a year-on-year increase of 10.54%, while the net profit attributable to shareholders dropped by 63.68% to 21 million yuan [4][5]. - The net cash flow from operating activities was negative at -78.93 million yuan [5]. - For Q1 2025, the company reported a revenue of 124 million yuan, a decline of 26.92%, and a net loss attributable to shareholders of -28.79 million yuan [6][7].
澳华内镜实控人方拟减持 上市募7.5亿1年1期扣非亏损